Total and Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease Registry

Dat T. Tran, PhD, a Walid Barake, MD, b Diane Galbraith, BN, MSc, c Colleen Norris, PhD, b Merrill L. Knudtson, MD, FRCP(c), c Padma Kaul, PhD, a,b Finlay A. McAlister, MD, PhD, a,b and Roopinder K. Sandhu, MD, MPH a,b

a Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada
b Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
c Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada

ABSTRACT
Background: Patients undergoing percutaneous coronary intervention (PCI) are increasingly older and have a higher comorbidity burden. This study evaluated trends in 30-day, 1-year, and 2-year total and cause-specific mortality using a large, contemporary cohort of patients who underwent PCI in Alberta, Canada.

Methods: We used the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) registry to identify patients aged ≥ 20 years who underwent PCI between 2005 and 2013. All patients were followed until death or being censored by August 2016. Cause of death was from the Vital Statistics database and classified as cardiac or noncardiac. Multivariable logistic regression was used to calculate predicted mortality at 30 days, 1 year, and 2 years post-PCI.

Results: Of the 35,602 patients who underwent PCI, 5284 (14.8%) had died. Mean (standard deviation) follow-up was 74.9 (35.1) years post-PCI. Of the deaths, 58% were attributed to a cardiac cause of death. In the first month post-PCI were more likely to experience a cardiac death; however, the rates of cardiac and noncardiac deaths were similar after the first month up to 1 year.

Percutaneous coronary intervention (PCI) is the most frequently performed revascularization procedure worldwide. Over the past 2 decades, the management of coronary artery disease has been revolutionized with advancements in PCI technique, equipment, and adjuvant therapies leading to increased procedural safety and success, reduced need for emergency coronary bypass artery graft surgery, and a marked decline in cardiovascular mortality. The characteristics of patients undergoing PCI has also changed, and the procedure is being performed in older individuals with greater comorbidity burden in recent years. Despite changes in clinical patient profiles, data regarding the contribution of cardiac and noncardiac causes of death after PCI are sparse. A retrospective study from a tertiary care center found a mortality rate of 2% within 30 days of PCI, with 58% being attributed to a cardiac cause of death. In the multicenter Evaluation of Drug Eluting Stents and Ischemic Events registry (EVENT) registry, patients who died within the first month post-PCI were more likely to experience a cardiac death; however, the rates of cardiac and noncardiac deaths were similar after the first month up to 1 year.

https://doi.org/10.1016/j.cjco.2019.05.003
2589-790X © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
months. Over the study period, patients were older and more likely to undergo PCI for an acute coronary syndrome indication. Thirty-day (2005: 1.3%; 2013: 3.2%; P < 0.001), 1-year (2005: 2.7%; 2013: 5.7%; P < 0.001), and 2-year (2005: 4.5%; 2013: 7.5%; P < 0.001) predicted mortality after PCI increased over the study period. Cardiac cause of death dominated in the short-term, but the proportion of noncardiac deaths increased as time from PCI to death increased (30 days = 11.5%, 1 year = 31.5%, 2 years = 39.6%; P < 0.001).

Conclusions: In this population-based study, we found all-cause mortality at 30 days, 1 year, and 2 years after PCI increased over time. Cardiac causes of death dominate in the short-term after PCI; however, noncardiac cause becomes a major driver of mortality in the long-term.

Cause-specific mortality in the long-term post-PCI was examined in a large single-center study from 1991 to 2008 showing a 50% decline in 5-year cardiac mortality. Little is known about the trend of total and cause-specific mortality in the short- and long-term among patients undergoing PCI in more recent years in an integrated health care setting reflecting real-world practice. Accordingly, we used the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) registry to answer this question.

Methods

APPROACH registry

The APPROACH registry is an ongoing prospective cohort study of all Alberta residents undergoing coronary angiograms since 1995. The database contains information on demographic characteristics, patient comorbidities, medications, laboratory, electrocardiogram and imaging, indication for angiogram, and procedural details. The information is entered into the registry by physicians and trained cardiac catheterization laboratory and health information specialists. The APPROACH research team meets routinely to generate reports and ensure database quality control. Data from APPROACH are supplemented and enhanced by merging the clinical registry data with the administrative data sets.

Study population

Using the APPROACH registry, we included patients aged \( \geq 20 \) years who underwent PCI between January 2005 and December 2013. Patients who underwent PCI during the previous 3 years were excluded to ensure new PCI episodes. If a patient had multiple PCIs during the study period, the first PCI was designated as the index PCI. All patients were followed until death or being censored by August 31, 2016, representing a minimum follow-up of 32 months for all patients.

Patient survival and time from angiogram or revascularization until death were ascertained through linkage with the Alberta Administrative Health Dataset/Vital Statistics. We used the International Classification of Diseases, 10th revision code on the death certificate, which was recorded by each patient’s attending physician to identify the most responsible cause of death and categorized it into cardiac (eg, ischemic heart diseases) and noncardiac (eg, neoplastic, respiratory, and digestive causes) groups. Details on cause of death are presented in Supplemental Table S1. Previous studies have confirmed the high accuracy of coding of cardiovascular diseases and stroke in administrative databases.

Outcomes

The main outcomes were temporal trends of all-cause mortality at 30 days, 1 year, and 2 years after the index PCI. Other outcomes included mortality over time from the last PCI and distribution of cardiac and noncardiac cause of death at each of the 30-day, 1-year, and 2-year time points after the last PCI according to PCI indication. The last PCI was selected for cause of death assessment to reflect the most proximal intervention for patients who had more than 1 PCI during the study period.

Statistical analysis

Baseline characteristics were reported for each year of the study and survival status (cardiac and noncardiac cause of death) within 30 days, 1 year, and 2 years after PCI. Descriptive statistics were reported as counts and percentage for categorical variables and mean (± standard deviation) for continuous variables. Univariate linear and logistic regression were used for trend test of continuous and binary variables, respectively. We developed 3 multivariable logistic regression models to calculate predicted mortality at 30 days, 1 year, and 2 years after index PCI using marginal standardization. For each model, the primary independent variables were patient sex, age, and year of index PCI as a categorical variable (with the year 2005 as the reference). We used the likelihood ratio test to examine inclusion of additional risk factors. They were patient comorbidities (Table 1) and angiographic and procedural characteristics (multivessel disease, left main \( \geq 70\)%, using drug-eluting or bare metal stents, complete revascularization, and radial access) as binary variables and history of
Table 1: Baseline Characteristics and Mortality Rates for 35,602 Patients Undergoing Percutaneous Coronary Intervention from 2005 to 2013

| Variable                          | All    | 2005   | 2006   | 2007   | 2008   | 2009   | 2010   | 2011   | 2012   | 2013   | P for trend |
|-----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------------|
| N patient                         | 35,602 | 3906   | 3829   | 3616   | 3821   | 3836   | 4037   | 4143   | 4139   | 4275   | < 0.001     |
| Age (y), mean (SD)                | 62.6 (11.9) | 62.2 (11.9) | 62.1 (11.9) | 62.5 (11.9) | 62.7 (12) | 62.4 (11.9) | 62.5 (11.9) | 63 (11.8) | 63.5 (12) | 65.5 (12) | < 0.001     |
| P for trend                        |        |        |        |        |        |        |        |        |        |        | 0.676       |
| Female (%)                        | 23.4   | 25.3   | 22.6   | 23.9   | 23     | 21.4   | 22.2   | 25.7   | 23.6   |        |             |
| Cardiovascular comorbidities (%)  |        |        |        |        |        |        |        |        |        |        |             |
| Hypertension                      | 69.1   | 67     | 67.5   | 69.6   | 68.9   | 69.9   | 71     | 69.5   | 69.7   | 68.8   | 0.007       |
| Hyperlipidemia                    | 71     | 79.5   | 77.3   | 72.5   | 71.7   | 69.9   | 70.5   | 67     | 66.4   | 65.8   | < 0.001     |
| Diabetes mellitus                 | 25     | 4      | 4      | 3.9    | 4.2    | 4      | 3.8    | 4.2    | 3.8    | 3.8    | 0.005       |
| Renal disease                     | 8.3    | 9.4    | 8.1    | 10.2   | 8.3    | 8.1    | 7.2    | 7.2    | 7.3    |        | < 0.001     |
| Heart failure                     | 16.2   | 20.7   | 20.4   | 17.3   | 17.1   | 16.7   | 14.2   | 14.3   | 12.4   | 13.2   | < 0.001     |
| Prior myocardial infarction       | 9.8    | 6.3    | 6.2    | 5.8    | 11     | 11.6   | 11.7   | 12.4   | 11.3   | 11.1   | < 0.001     |
| Peripheral vascular disease       |        |        |        |        |        |        |        |        |        |        |             |
| Noncardiac comorbidities (%)      |        |        |        |        |        |        |        |        |        |        |             |
| Pulmonary disease                 | 12.9   | 13.6   | 12.5   | 11.6   | 12.4   | 12.8   | 13.7   | 13.2   | 14.1   | 12.1   | 0.464       |
| Malignancy                        | 3.5    | 3.8    | 3.5    | 4      | 3.2    | 3.3    | 3.9    | 3.3    | 3.6    | 3.2    | 0.155       |
| Liver disease                     | 0.7    | 0.8    | 0.5    | 0.5    | 0.4    | 0.8    | 0.7    | 0.7    | 0.7    |        | 0.171       |
| Cerebrovascular disease           | 5.1    | 6      | 5.9    | 6.1    | 4.7    | 5.2    | 5.1    | 5.1    | 4.4    | 4      | < 0.001     |
| Repeat PCI within 90 d (%)        | 8.1    | 7.7    | 7.1    | 7.4    | 7.9    | 7.7    | 8      | 8.4    | 9.5    | 8.9    | < 0.001     |
| History of smoking (%)            |        |        |        |        |        |        |        |        |        |        |             |
| Never                             | 37.2   | 30     | 34.2   | 36.9   | 38.1   | 37.6   | 37.8   | 37     | 40     | 42.7   | < 0.001     |
| Current                           | 32.8   | 30.7   | 33.3   | 33.9   | 33.3   | 32.6   | 34.2   | 34     | 32.7   | 31     | 0.980       |
| Past                              | 29.9   | 39.3   | 32.5   | 29.2   | 28.6   | 29.8   | 27.9   | 29     | 27.3   | 26.3   | < 0.001     |
| Indication for catheterization (%)|        |        |        |        |        |        |        |        |        |        |             |
| STEMI                             | 33.0   | 30.7   | 31.2   | 32.9   | 32.2   | 32.4   | 34.1   | 34.3   | 34.8   | 34.1   | < 0.001     |
| NSTEMI                            | 28.6   | 20.3   | 27.8   | 30.2   | 29.8   | 29.6   | 28.6   | 30.3   | 29.9   | 30.8   | < 0.001     |
| Unstable angina                   | 12.0   | 15.6   | 13.7   | 11.6   | 12.6   | 12     | 11.2   | 10.2   | 10.3   | 10.8   | < 0.001     |
| Stable angina                     | 20.3   | 21.3   | 21.8   | 18.8   | 20     | 21.2   | 20.6   | 20.5   | 19.3   | 19.4   | 0.019       |
| Other                             | 6.1    | 12.1   | 5.5    | 6.5    | 5.5    | 4.8    | 5.5    | 4.8    | 5.7    | 4.9    | < 0.001     |
| Angiographic and procedural       |        |        |        |        |        |        |        |        |        |        |             |
| characteristics (%)               |        |        |        |        |        |        |        |        |        |        |             |
| Multivessel disease               | 48.4   | 64.2   | 63     | 44.8   | 44.7   | 43.2   | 43.3   | 44.4   | 43.3   | 45.6   | < 0.001     |
| Left main > 70%                   | 2.3    | 1.8    | 1.9    | 1.5    | 2.1    | 2.3    | 2.6    | 2.6    | 2.6    | 2.9    | < 0.001     |
| Drug-eluting stent                | 41.1   | 48.7   | 37.1   | 27.7   | 32.7   | 37.2   | 38.5   | 40.5   | 47.4   | 56.8   | < 0.001     |
| Bare metal stent                  | 55.4   | 51.7   | 59.5   | 68.1   | 63.4   | 59.2   | 57.8   | 55.1   | 48.3   | 39.1   | < 0.001     |
| Complete revascularization        | 67.9   | -      | -      | 84.5   | 76.4   | 65.9   | 64.6   | 63.5   | 62.8   | 60.6   | < 0.001     |
| Total mortality (%)               |        |        |        |        |        |        |        |        |        |        |             |
| 30 d                              | 2.1    | 1.5    | 1.8    | 2.1    | 2.1    | 1.9    | 2.6    | 2.3    | 2      | 2.7    | 0.001       |
| 1 y                               | 4.2    | 3.3    | 3.6    | 3.9    | 4.1    | 3.9    | 4.8    | 4.5    | 4.3    | 5.1    | < 0.001     |
| 2 y                               | 6      | 5.2    | 5.1    | 5.6    | 5.6    | 6.1    | 6.7    | 6      | 6      | 6.9    | < 0.001     |

NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST-elevation myocardial infarction.
smoking and indication for PCI as categorical variables. Except for the primary variables, an independent variable remained in the final models if the likelihood ratio test was significant at a $P < 0.05$. Hosmer–Lemeshow goodness-of-fit test was used to check for model fits.

In addition, we calculated cardiac and noncardiac mortality after the last PCI using Kaplan–Meier curve and reported as a percentage of the total deaths at each of the 30-day, 1-year, and 2-year time points. All analyses were performed using Stata version 14 (StataCorp LP, College Station, TX). A 2-sided $P$ value $< 0.05$ was considered statistically significant.

The study was approved by the Health Research Ethics Board at the University of Alberta (Pro00040868).

Results

Baseline characteristics

Between 2005 and 2013, there were 37,195 patients aged $\geq 20$ years who underwent PCI in Alberta, Canada. After excluding patients who had PCI during the previous 3 years ($n = 1953$), the final study cohort included 35,602 patients with a mean (standard deviation) follow-up time of 74.9 (35.1) months. Of them, 5580 (15.7%) had more than 1 PCI during the study period. Patient age (mean = 62.6 years) increased over time (2005: mean = 62.2 years; 2013: mean = 63.5 years; $P < 0.001$). There were less female (23.4%) than male patients, and this trend remained during the study period ($P = 0.676$). Hypertension (69.1%) and hyperlipidemia (71%) were the most prevalent cardiovascular comorbidities. Although hypertension increased (2005: 67%; 2013: 68.8%; $P < 0.001$), hyperlipidemia decreased (2005: 79.5%; 2013: 65.8%; $P < 0.001$). ST-elevation myocardial infarction (STEMI, 33%) was the most common indication for catheterization, and it increased over time (2005: 30.7%; 2013: 34.1%; $P < 0.001$). The proportion of patients who underwent drug-eluting stent increased (2005: 48.7%; 2013: 56.8%; $P < 0.001$), whereas that of those undergoing bare metal stent decreased (2005: 51.7%; 2013: 39.1%; $P < 0.001$) during the study period (Table 1). Characteristics of patients by survival status is presented in Supplemental Table S2.

All-cause mortality

Overall, 5284 patients (14.8%) died during the study period. Unadjusted mortality increased over time at all 3 time points: 30 days (2005: 1.5%; 2013: 2.7%; $P = 0.001$), 1 year (2005: 3.3%; 2013: 5.1%; $P < 0.001$), and 2 years (2005: 5.2%; 2013: 6.9%; $P < 0.001$) (Table 1). The increasing trends remained after risk adjustments. The predicted 30-day mortality increased from 1.3% (95% confidence interval [CI], 0.9-1.6) in 2005 to 3.2% (95% CI, 2.6-3.7) in 2013 ($P < 0.001$). Likewise, the predicted mortality increased from 2.7% (95% CI, 2.2-3.2) in 2005 to 5.7% (95% CI, 5-6.4) in 2013 ($P < 0.001$) and from 4.5% (95% CI, 3.9-5.1) in 2005 to 7.5% (95% CI, 6.7-8.2) in 2013 ($P < 0.001$) at 1 year and 2 years post-PCI, respectively (Fig. 1). Results of multivariable logistic regression models for mortality at 30 days, 1 year, and 2 years after index PCI are presented in Supplemental Table S3.

Cause-specific mortality

Of all deaths, 40% were cardiac and 48% were noncardiac (Fig. 2). The most common cardiac causes of death were chronic ischemic heart disease (18%) and acute myocardial infarction (17%), and the most common causes of noncardiac causes were malignant neoplasm (20%) and diseases of the respiratory system (6%). The proportion of cardiac and noncardiac cause of death from last PCI at 30 days, 1 year, and 2 years by PCI indication is presented in Table 2. Cardiac causes of death were the most common at all 3 time points, but the proportion of noncardiac causes increased as time from PCI did (30 days: 11.5%; 1 year: 31.5%; 2 years: 39.6%; $P < 0.001$). The major drivers for this trend were fewer fatal myocardial infarctions (63.3% and 29.7% of all deaths at 30 days and 2 years post-PCI, respectively, $P < 0.001$) and more deaths resulting from lung neoplasms (0.7% and 4.5% of all deaths at 30 days and 2 years post-PCI, respectively, $P < 0.001$).

Overall, noncardiac cause of death surpassed cardiac cause after 3 years from the last PCI and remained the most common cause thereafter (Fig. 3). Cardiac death dominated during the first 6 years after the last PCI for patients with
STEMI, whereas noncardiac causes did at 1 year for patients who had stable angina and 2 years for those who had non-STEMI or unstable angina (Table 2, Fig. 4).

Discussion

Our population-based study of 35,602 patients undergoing PCI using a real-world prospective clinical registry over 9 years showed that all-cause mortality at 30 days, 1 year, and 2 years after PCI increased over time. Overall, cardiac causes accounted for a smaller proportion of death compared with noncardiac reasons, but it dominated in the short-term after PCI and subsequently decreased as time from PCI increased. By the third year after PCI, noncardiac cause became the major driver of mortality. Patients with STEMI had the highest burden of cardiac mortality, and this remained dominant until the sixth year post-PCI.

Similar to our study, which included a more contemporary time period, studies from both the United States and Sweden have found mortality rates after PCI have increased in recent years. When evaluating 1-year mortality rates, Fokkema et al. reported a slight decrease, whereas we found both unadjusted and adjusted 1-year mortality rates after PCI increased over time. The differences in trends could be explained by differences in level of risk adjustment. In our study, we adjusted for not only age and indication for PCI but also patient and angiographic factors. Additionally, the decrease in mortality observed in the Sweden study was mainly among patients with STEMI, which increased 5-fold over the study period, but only increased 3.4% in our cohort. Furthermore, the increasing trends of mortality after PCI in our study may be the result of a patient population with a higher risk profile (ie, the elderly) or broader indication, such as patients with complex lesions for whom it was previously not recommended, or the degree of complete revascularization.

We found that traditional cardiac risk factors (hypertension, hyperlipidemia) confer a reduction in the odds of all-cause mortality. Improved use of evidence-based medicine

Table 2. Proportion of cardiac and noncardiac mortality at 30 days, 1 year, and 2 years after the last PCI according to indication for PCI

| Indication for PCI | 30 d | 1 y | 2 y |
|--------------------|------|-----|-----|
| All indications    |      |     |     |
| All-cause mortality (%) | 2.3  | 4.5 | 6.4 |
| Cardiac mortality (%)  | 82.6 | 64.1| 55.1|
| Noncardiac mortality (%) | 11.5 | 31.5| 39.6|
| STEMI               |      |     |     |
| All-cause mortality (%) | 4.6  | 6.8 | 8.2 |
| Cardiac mortality (%)  | 84.4 | 73.1| 66.3|
| Noncardiac mortality (%) | 9.8  | 21.8| 28.1|
| NSTEMI             |      |     |     |
| All-cause mortality (%) | 1.4  | 4.2 | 6.2 |
| Cardiac mortality (%)  | 78.4 | 54.6| 48.6|
| Noncardiac mortality (%) | 15.8 | 42.8| 48  |
| Unstable angina    |      |     |     |
| All-cause mortality (%) | 0.8  | 2.3 | 4.5 |
| Cardiac mortality (%)  | 82.4 | 55.9| 44.4|
| Noncardiac mortality (%) | 14.7 | 41.2| 49.5|
| Stable angina      |      |     |     |
| All-cause mortality (%) | 0.2  | 1.5 | 3.1 |
| Cardiac mortality (%)  | 53.3 | 43.2| 34.6|
| Noncardiac mortality (%) | 33.3 | 51.7| 58.5|

NSTEMI, non—ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

Figure 2. Causes of death after PCI in Alberta, 2005-2013.

Figure 3. Cumulative all-cause and cause-specific mortality after PCI in Alberta, 2005-2013.
to treat risk factors may contribute to this finding.\textsuperscript{20-22} A radial approach was also associated with a decreased risk of mortality. Compared with a femoral approach, multiple randomized clinical trials have demonstrated a mortality benefit with a radial approach that is primarily driven by a reduction in bleeding complications.\textsuperscript{23-26}

Few studies have evaluated the differential timing of cardiac and noncardiac cause of death after PCI in clinical practice and found a cardiac reason for death in the short-term ranging from 58\% to 70\% in the United States and 92\% in Denmark.\textsuperscript{8,10,27} The lower proportions of cardiac cause of death in the US cohorts might be due to differences in patient risk profiles (ie, older population in the US cohorts, possibly making them more vulnerable to noncardiac reasons such as cancer or pulmonary diseases).\textsuperscript{8,10,27} Stolker et al.\textsuperscript{10} reported 25\% undetermined cause of death and variations in patterns of practice between jurisdictions as possibly affecting patient outcomes.\textsuperscript{28}

Although cardiac mortality dominates in the short-term post-PCI, we found the proportion of noncardiac deaths surpasses cardiac mortality in the long-term follow-up as previously reported. Spoon et al.\textsuperscript{9} reported a significant shift to noncardiac cause of death in 2014. Similar trends from cardiac to noncardiac cause of death after PCI have also been observed specifically in patients with STEMI.\textsuperscript{29} Pedersen et al.\textsuperscript{27} reported higher noncardiac deaths at 6 years after PCI in patients with STEMI in Denmark, approximately the same as the convergence time for patients with STEMI in our study. Likewise, Yamashita et al.\textsuperscript{30} reported only 9\% of noncardiac cause of death at 6 months but 4.5 times increase to 41\% at 7 years after PCI in Japan.

This decline in cardiac reasons for mortality in our study and a prior report of long-term follow-up are mainly due to fewer fatal myocardial infarctions and increasing malignancy rates.\textsuperscript{9} Patient characteristics (ie, older patients with a higher burden of noncardiovascular comorbidities)\textsuperscript{8,10,27} may predispose to noncardiac reasons for mortality, particularly because advancements in revascularization technology, high procedural success rates, and use of secondary prevention therapies have lowered long-term cardiac mortality.\textsuperscript{3,8,20,21} Further research may be warranted to integrate the roles of noncardiac cause of death into clinical guidelines and best practices regarding cardiac health.

\textbf{Study limitations}

Although our study was conducted using a clinical registry in a single-payer, universally covered, and integrated health system, which serves more than 4 million people in a large geographical area of Alberta, there are limitations that warrant discussion. First, our study did not capture medications at discharge or during follow-up, and this could have affected the adjusted balance between cardiac and noncardiac mortality rates, particularly because secondary prevention medication has been shown to improve long-term cardiac survival after PCI.\textsuperscript{20,22} Second, we had missing data for the variable complete revascularization in 2005-2006, and we are unable to differentiate the specific causes of death under the broader categories (ie, cause of death under chronic ischemic heart
of Drug Eluting Stents and Ischemic Events registry. Am Heart J 2011;162:914-21.
11. Ghali WA, Knudston ML. Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators. Can J Cardiol 2000;16:1225-30.
12. Norris CM, Ghali WA, Knudston ML, Naylor CD, Saunders LD. Dealing with missing data in observational health care outcome analyses. J Clin Epidemiol 2000;53:377-83.
13. Alberta Health. Overview of Administrative Health Datasets. Available at: https://open.alberta.ca/dataset/657/ed26d-e4b2-4632-9bcb-0ca2158f165d/resource/38f47433-b33d-4dd1-e-b959-d512e9d9855/download/Research-Health-Datasets.pdf. Accessed December 1, 2017.
14. Patel AB, Quan H, Walsh RC, et al. Validity and utility of ICD-10 administrative health data for identifying ST- and non-ST-elevation myocardial infarction based on physician chart review. CMAJ Open 2015;3:E413-8.
15. McCormick N, Bhole V, Lacaille D, Avina-Zubieta JA. Validity of diagnostic codes for acute stroke in administrative databases: a systematic review. PLoS One 2015;10:e0135834.
16. Tu JV, Nardi L, Fang J, et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004. CMAJ 2009;170:E118-25.
17. Muller CJ, MacLehose RF. Estimating predicted probabilities from logistic regression: different methods correspond to different target populations. Int J Epidemiol 2014;43:962-70.
18. Singh M, Mathew V, Garratt KN, et al. Effect of age on the outcome of angiplasty for acute myocardial infarction among patients treated at the Mayo Clinic. Am J Med 2000;108:187-92.
19. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paltaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010;121:2645-53.
20. Jaber WA, Lennon RJ, Mathew V, et al. Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. J Am Coll Cardiol 2005;46:1473-8.
21. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011;58:2432-46.
22. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-12.
23. Bernat I, Horak D, Stasek J, et al. ST-segment elevation myocardial infarction treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial. J Am Coll Cardiol 2014;63:964-72.
24. Romagnoli E, Biondi-Zoccai G, Schiahbai A, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol 2012;60:2481-9.
Supplementary Material

To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca and at https://doi.org/10.1016/j.cjco.2019.05.003.